Toboroz
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
NCT07773727· 2. fázis· argenx· Forrás
Toboroz
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
NCT07890454· 3. fázis· Sanofi· Forrás
Toboroz
A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight
2025-524616-11-00· 3. fázis· AstraZeneca AB· Forrás
Még nem toboroz
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· 3. fázis· Pharmacosmos A/S· Forrás
Még nem toboroz
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· 3. fázis· Genmab A/S· Forrás
Még nem toboroz
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
NCT07340658· 3. fázis· Rovi Pharmaceuticals Laboratories· Forrás
Toboroz
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135· 3. fázis· AstraZeneca· Forrás
Még nem toboroz
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
NCT07665853· 3. fázis· Hospital Universitari Vall d'Hebron Research Institute· Forrás
Toboroz
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00· 3. fázis· Zai Lab (US) LLC· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Még nem toboroz
PRIME Trial - Primary Respiratory Infection and Microbiological Eradication Trial
2025-524454-34-00· 4. fázis· Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· 2. fázis· SOLTI Breast Cancer Research Group· Forrás
Toboroz
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· 3. fázis· Sanofi· Forrás
Toboroz
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo
in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
2025-521562-95-00· 3. fázis· Mabxience Research S.L.· Forrás
Fut, nem toboroz
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
NCT07162883· 3. fázis· Qilu Pharmaceutical Co., Ltd.· Forrás
Toboroz
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767· 3. fázis· Olema Pharmaceuticals, Inc.· Forrás
Toboroz
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· 2. fázis· GlaxoSmithKline· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás
Toboroz
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· 2. fázis· CSL Behring· Forrás
Még nem toboroz
Exploring the Anti-ageing Effects of Metformin in COPD
NCT06999343· 3. fázis· Fundación Instituto de Investigación Sanitaria de Navarra· Forrás
Toboroz
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás
Toboroz
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· 3. fázis· Celcuity Inc· Forrás
Toboroz
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· 3. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· 2. fázis· MedSIR· Forrás
Toboroz
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
The role of intra-abdominal pressure and point of care ultrasound to guide decongestive therapy in Heart Failure (ABDOPOCUS-HF)
2024-512901-22-00· 3. fázis· Fundacion Instituto De Investigacion Sanitaria Aragon· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Toboroz
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384· 2. fázis· UNICANCER· Forrás
Toboroz
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· 3. fázis· Cytokinetics· Forrás
Fut, nem toboroz
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
NCT06668558· 2. fázis· Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias· Forrás
Toboroz
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· 3. fázis· MedSIR· Forrás
Toboroz
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
NCT06435429· 3. fázis· Jazz Pharmaceuticals Ireland Limited· Forrás
Toboroz
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285· 2. fázis· Puma Biotechnology, Inc.· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Toboroz
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
NCT06058585· 3. fázis· The George Institute· Forrás
Fut, nem toboroz
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· 3. fázis· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Forrás
Toboroz
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
2023-508435-31-00· 1. fázis· Onkure Inc.· Forrás
Fut, nem toboroz
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Fut, nem toboroz
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· 3. fázis· Lysarc· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552· 3. fázis· argenx· Forrás
Fut, nem toboroz
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837· 1/2. fázis· Pfizer· Forrás
Showing 50 of 81.